The Europe Amniocentesis Needle Market would witness market growth of 6.5% CAGR during the forecast period (2023-2030).
Needle-based diagnostics, such as amniocentesis, offer high accuracy in detecting fatal chromosomal abnormalities and genetic disorders. This accuracy is crucial for expectant parents and healthcare providers to make informed decisions about the pregnancy and prepare for any potential health challenges the baby may face. Amniocentesis is considered the gold standard for diagnosing chromosomal abnormalities, such as Down syndrome, Edwards syndrome, and Patau syndrome, as well as other genetic conditions.
In addition, needle-based diagnostics are particularly valuable in high-risk pregnancies, including those with advanced maternal age, a history of chromosomal abnormalities in previous pregnancies, or abnormal ultrasound findings. In such cases, amniocentesis provides essential information for prenatal counselling, medical management, and decision-making. Moreover, obstetric ultrasound has become increasingly sophisticated, allowing for high-resolution imaging of the foetus and surrounding structures.
Based on data from the International Trade Administration (ITA), the projected turnover for the medical device industry in France in 2022 amounts to €36.7 billion. It is estimated that medical device exports from France generate a turnover of €9.4 billion, or 26% of the total market. The industry is expected to expand by approximately 2% per year over the next few years. Additionally, according to the Office For National Statistics, in 2020, the U.K. incurred £257.6 billion in total current healthcare expenditures, equivalent to £3,840 per person. In 2020, the aggregate current healthcare expenditure in the United Kingdom comprised 12.0% of the country's gross domestic product, up from 9.9% in 2019. Therefore, the growing medical device industry and high expenditure in the region's healthcare sector propel the market's growth.
The Germany market dominated the Europe Amniocentesis Needle Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $20,235.3 Million by 2030. The UK market is exhibiting a CAGR of 5.6% during (2023 - 2030). Additionally, The France market would experience a CAGR of 7.3% during (2023 - 2030).
Free Valuable Insights: The Global Amniocentesis Needle Market will Hit $283.8 Million by 2030, at a CAGR of 6.7%
Based on Procedure, the market is segmented into Amniocentesis Procedures, Fetal Blood Transfusion, Amnioreduction Procedures, Amnioinfusion Procedure, and Cordocentesis Procedure. Based on End-use, the market is segmented into Hospitals, Diagnostics centers, Clinics, and Others. Based on Type, the market is segmented into 100 to 150 mm, Larger Than 150 mm, and Smaller Than 100 mm. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
By Procedure
By End-use
By Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
